RNA干扰介导的抗HIV治疗研究进展

生物技术通报 ›› 2013, Vol. 0 ›› Issue (5): 28-33.

RNA干扰介导的抗HIV治疗研究进展

杨文思¹, 王沂², 王洋³

(1.河北大学生命科学学院，保定 071000 ；2.河北联合大学附属医院，唐山 063000；3.河北联合大学生命科学学院，唐山 063000)

收稿日期:2012-11-27 修回日期:2013-05-24 出版日期:2013-05-24 发布日期:2013-05-24
作者简介:杨文思，女，研究方向：生物化学与分子生物学；E-mail：qingren32497@sohu.com
基金资助:
河北青年科学基金项目(C2012401039)

Research Progress of Anti-HIV Therapy Mediated by RNAi

Yang Wensi¹, Wang Yi², Wang Yang³

(1. College of Life Sciences，Hebei University，Baoding 071000；2. Hebei United University Affiliated Hospital，Tangshan 063000；3. College of Life Sciences，Hebei United University，Tangshan 063000)

Received:2012-11-27 Revised:2013-05-24 Published:2013-05-24 Online:2013-05-24
About author:王洋，男，博士，讲师，研究方向：疾病相关新基因；E-mail：ricaniidae@yahoo.com.cn

摘要/Abstract

摘要： 人类免疫缺陷病毒(HIV)是引起获得性免疫缺陷综合征(AIDS)的病原体，即艾滋病，目前尚无有效的治愈方法，严重危害着人类的健康。RNA 干扰(RNAi)是一种由双链RNA 所引起的序列特异性基因沉默，被广泛应用于生物医学研究。目前，已经有多个研究机构将RNAi作为对抗HIV感染的可行手段并通过试验进行了验证，其采取的方法主要包括靶向siRNA治疗和载体介导的shRNA治疗。就HIV RNAi治疗的研究现状作一综述。

关键词: HIV, RNAi, siRNA, shRNA, 靶向治疗, 适体, 慢病毒载体

Abstract: Human immunodeficiency virus(HIV)is the pathogen of Acquired Immune Deficiency Syndrome(AIDS), which is an incurable disease and has become a serious public health problem. RNA interference (RNAi) is a post-transcriptional process triggered by the introduction of double-stranded RNA (dsRNA) which leads to gene silencing in a sequence-specific manner. RNAi technology has been widely used in biological and medical research. At present, many researchers have taken RNAi technology as a possible anti-HIV method and tested it in experiments. The main means in RNAi mediated anti-HIV experiments included siRNA targeted therapy and shRNA plasmid mediated therapy. This article will review the research progress of anti-HIV therapy mediated by RNAi.

Key words: HIV, RNAi, siRNA, shRNA, Targeting therapy, Aptamer, Lentivector

杨文思, 王沂, 王洋. RNA干扰介导的抗HIV治疗研究进展[J]. 生物技术通报, 2013, 0(5): 28-33.

Yang Wensi, Wang Yi, Wang Yang. Research Progress of Anti-HIV Therapy Mediated by RNAi[J]. Biotechnology Bulletin, 2013, 0(5): 28-33.

参考文献

[1] Tijsterman M, Ketting RF, Plasterk RH. The genetics of RNA silencing[J]. Annu Rev Genet, 2002, 36：489-519.
[2] Tsygankov AY. Current developments in anti-HIV/AIDS gene therapy[J]. Curr Opin Investig Drugs, 2009, 10(2)：137-149.
[3] Singh SK, Gaur RK. Progress towards therapeutic application of RNA interference for HIV infection[J]. BioDrugs, 2009, 23(5)：269-276.
[4] Chan JK, Greene WC. Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis[J]. Immunol Rev, 2012, 246(1)：286-310.
[5] Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition[J]. J Virol, 2004, 78(5)：2601-2605.
[6] Pusch O, Boden D, Silbermann R, et al. Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA[J]. Nucleic Acids Res, 2003, 31(22)：6444-6449.
[7] Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV[J]. Nat Biotechnol, 2007, 25(12)：1444-1454.
[8] Shah PS, Pham NP, Schaffer DV. HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites[J]. Mol Ther, 2012, 20(4)：840-848.
[9] Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen[J]. Science, 2008, 319(5865)：921-926.
[10] K?nig R, Zhou Y, Elleder D, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication[J]. Cell, 2008, 135(1)：49-60.
[11] Zhou H, Xu M, Huang Q, et al. Genome-scale RNAi screen for host factors required for HIV replication[J]. Cell Host Microbe, 2008, 4(5)：495-504.
[12] Dziuba N, Ferguson MR, O'Brien WA, et al. Identification of cellu-lar proteins required for replication of human immunodeficiency virus type 1[J]. AIDS Res Hum Retroviruses, 2012, 28(10)：1329-1339.
[13] Kok KH, Lei T, Jin DY. siRNA and shRNA screens advance key understanding of host factors required for HIV-1 replication[J]. Retrovirology, 2009, 6：78.
[14] Pache L, K?nig R, Chanda SK. Identifying HIV-1 host cell factors by genome-scale RNAi screening[J]. Methods, 2011, 53(1)：3-12.
[15] Eekels JJ, Sagnier S, Geerts D, et al. Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors[J]. Virol J, 2012, 9(1)：69.
[16] De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus[J]. Retrovirology, 2011, 8：98.
[17] Friedrich BM, Dziuba N, Li G, et al. Host factors mediating HIV-1 replication[J]. Virus Res, 2011, 161(2)：101-114.
[18] Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice[J]. Cell, 2008, 134(4)：577-586.
[19] Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors[J]. Nat Biotechnol, 2005, 23(6)：709-717.
[20] Kim SS, Peer D, Kumar P, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice[J]. Mol Ther, 2010, 18(2)：370-376.
[21] Neff CP, Zhou J, Remling L, et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice[J]. Sci Transl Med, 2011, 3(66)：66ra6.
[22] Zhou J, Rossi JJ. Aptamer-targeted RNAi for HIV-1 therapy[J]. Methods Mol Biol, 2011, 721：355-371.
[23] Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras[J]. J Clin Invest, 2011, 121(6)：2401-2412.
[24] Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation[J]. N Engl J Med, 2009, 360(7)：692-698.
[25] Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy[J]. Mol Ther, 2005, 12(5)：900-909.
[26] Walker JE, Chen RX, McGee J, et al. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector[J]. J Virol, 2012, 86(10)：5719-5729.
[27] Bobadilla S, Sunseri N, Landau NR. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein[J]. Gene Ther, 2012 doi：10.1038/gt.2012.61.
[28] Zhang T, Cheng T, Wei L, et al. Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct[J]. Virol J, 2012, 9：118.
[29] Chung J, Zhang J, Li H, et al. Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy[J]. Hum Gene Ther, 2012, 23(11)：1200-1208.
[30] Kiem HP, Wu RA, Sun G, et al. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo[J]. Gene Ther, 2010, 17(1)：37-49.
[31] Low JT, Knoepfel SA, Watts JM, et al. SHAPE-directed discovery of potent shRNA inhibitors of HIV-1[J]. Mol Ther, 2012, 20(4)：820-828.
[32] Tyagi A, Ahmed F, Thakur N, et al. HIVsirDB：a database of HIV inhibiting siRNAs[J]. PLoS One, 2011, 6(10)：e25917.